Cellectis - ADR

NASDAQ:CLLS  
6.60
-0.13 (-1.93%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)295.24M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$11.55 Million
Adjusted EPS-$0.88
See more estimates
10-Day MA$7.19
50-Day MA$8.44
200-Day MA$12.90
See more pivots

Cellectis - ADR Stock, NASDAQ:CLLS

8, rue de la Croix Jarry, Paris, Ile-de-France 75013
France
Phone: +33.1.81.69.16.00
Number of Employees: 281
http://www.cellectis.com

Description

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. It offers Gene editing and Immuno-oncology. The company was founded by David J. Sourdive and Andr�© Choulika on February 20, 1999 and is headquartered in Paris, France.